MicroRNA Therapies Market Size Worth $7 Billion By 2030: IndustryARC

The Global MicroRNA Therapies Market size is predicted to reach $7 billion by 2030, growing at a CAGR of 12.5% during the forecast period 2024-2030 according to the latest market research report published by IndustryARC. The rapid development and regulatory approval of emerging miRNA-based therapeutics are fueling the growth of the MicroRNA Therapies Market during the forecast period, finds IndustryARC in its recent report, titled “MicroRNA Therapies Market Size, Share & Trends Analysis Report By Product Type (miRNA Mimics, Antagomirs or Inhibitors), By Technology (Microarrays, Next Generation Sequencing (NGS), Quantitative Real-Time PCR (qRT-PCR), Northern Blotting, and In Situ Hybridization (ISH)), By Application (Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Diseases, Neurological Diseases and Other),  By End-User (Biotechnology & Pharmaceutical Companies, Academic and government research institutes, Others), By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030.”

During the forecast period of 2024-2030, the North America region has market share 35% in the global MicroRNA Therapies market due to its dynamic and creative healthcare ecosystem. The region has a strong network of R&D centres, which include prestigious institutions, universities, and cutting-edge biotechnology firms. These entities actively contribute to the investigation of innovative therapeutic routes, such as the creation of MicroRNA-based therapies.

 

As per the MicroRNA Therapies Market forecast, the Cancer sector is estimated to grow at the fastest CAGR of 13.8% during the forecast period in terms of application which offers a targeted and personalized approach to cancer treatment and has shown tremendous promise in the field of oncology. Because of the high prevalence of cancer in the region, there is a greater emphasis on creating novel and effective therapy options. North American academic institutes and biotechnology firms have been at the forefront of utilizing microRNAs' potential to alter gene expression and regulate key pathways involved in cancer progression.

As per the MicroRNA Therapies Market analysis, the Academic and Government Research Institutes segment is projected to exhibit the highest growth during the forecast period in terms of end-user due to their contributions to scientific understanding, innovation, and regulatory advancements. These institutes serve as cutting-edge research hubs, laying the groundwork for the development of MicroRNA-based therapeutics. In these situations, researchers frequently investigate the complex mechanisms of MicroRNA regulation, discover new therapeutic targets, and undertake preclinical studies to validate the efficacy and safety of MicroRNA therapeutics. Their discoveries not only improve our understanding of the underlying biological mechanisms but also provide useful information for optimizing therapeutic therapies. In addition, academia and government organizations routinely engage with commercial partners and pharmaceutical companies to put research discoveries into practical medicinal applications.

Significant advances in molecular biology and genomics are propelling the expansion of the MicroRNA Therapies market, leading to a better understanding of the complex regulatory roles that microRNAs play in gene expression. Researchers are identifying distinct microRNA profiles linked to a variety of disorders, providing significant insight into possible treatment targets. Pharmaceutical companies are more positioned to produce highly targeted and effective MicroRNA therapeutics as the information base grows. This enhanced understanding of disease molecular pathways improves the precision and therapeutic potential of MicroRNA-based therapies, propelling the market ahead.

The effective delivery of microRNAs to target tissues is one of the key problems confronting the MicroRNA Therapies industry. MicroRNAs are intrinsically fragile and can be rapidly destroyed in the bloodstream, making sufficient quantities at the target areas of action difficult to achieve. Furthermore, ensuring that microRNAs are delivered to the appropriate tissues while avoiding off-target effects remains a substantial challenge. The study of reliable and targeted delivery mechanisms, such as nanoparticles or viral vectors, is underway. Overcoming these delivery issues is critical for optimizing MicroRNA therapeutic efficacy and realizing their full promise in clinical settings.

Neurological illnesses such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS) present a significant market opportunity for the development of MicroRNA Therapies. These complex and difficult illnesses frequently lack effective disease-modifying therapies, resulting in a huge unmet demand. MicroRNAs serve critical functions in the nervous system's gene expression regulation, and deregulation of certain microRNAs has been linked to a variety of neurological illnesses. The opportunity is to create MicroRNA therapeutics that can modify these dysregulated pathways, perhaps delaying disease development or easing symptoms. Understanding the biological underpinnings of neurological illnesses, as well as the involvement of microRNAs in these situations, lays the groundwork for therapeutic development.

MicroRNA Therapies have great potential in the treatment of uncommon genetic illnesses, when established therapeutic options are frequently limited. The discovery of specific microRNAs linked to uncommon genetic illnesses opens the door to the creation of targeted medicines to rectify or modify the underlying genetic defects. The capacity of MicroRNA treatments to fine-tune gene expression gives them a distinct edge in tackling the complicated molecular pathways behind uncommon hereditary illnesses.

The market opportunity for developing targeted and precision medicines grows as advances in genomics and molecular diagnostics enable the detection of uncommon genetic variants and associated microRNA dysregulation. This particular domain enables the tailoring of MicroRNA therapeutics to address the specific genetic abnormalities associated with each rare disease, providing hope for individuals with few therapy alternatives. The growing acceptance of microRNA treatments as a viable treatment option for rare genetic illnesses presents a significant market opportunity for innovation and expansion.

The world's ageing population represents a tremendous market opportunity for MicroRNA Therapies, particularly in the context of cardiovascular disorders. As people get older, the prevalence of cardiovascular illnesses including heart failure and atherosclerosis rises, generating a significant unmet medical need. MicroRNAs are important regulators of cardiovascular function, and their dysregulation is frequently linked to the aetiology of cardiovascular disease. MicroRNA treatments' unique ability to target the underlying molecular causes of cardiovascular diseases makes them interesting candidates for therapeutic development in this arena. The market opportunity is heightened by the worldwide ageing population, emphasising the potential impact of MicroRNA Therapies on cardiovascular health in the context of a rising demographic in need of effective and focused therapies.

 

● MicroRNA Therapies Market Size and Forecast 

● MicroRNA Therapies Market Trends

● MicroRNA Therapies Market Analysis by Deployment Type

● CAGR of the market during the forecast period 2024-2030

● Value Chain analysis of key stake holders

● Detailed analysis of market drivers and opportunities during the forecast period

● MicroRNA Therapies Market size estimation and forecast

● Analysis and predictions on end users’ behavior and upcoming trends 

● Competitive landscape and Vendor market analysis including offerings, developments, and financials

● Comprehensive analysis of challenges and constraints in the MicroRNA Therapies Market

The Covid-19 epidemic has had a complex and multifaceted impact on the MicroRNA Therapies market's growth trajectory. On the one hand, the pandemic has highlighted the critical need for novel therapeutic techniques, particularly those based on microRNA, to address the virus's problems. This has the potential to increase attention and funding in the development of MicroRNA Therapies as a promising antiviral therapy route. The pandemic, on the other hand, has changed the overall healthcare landscape, diverting resources and attention to immediate and pressing public health concern.

The ongoing Russia-Ukraine conflict has cast a shadow on various industries, including the field of MicroRNA Therapies. The cumulative impact of the Russia-Ukraine conflict, on the other hand, is expected to have major long-term implications on the worldwide MicroRNA market. Unfortunately, the available search results do not provide particular facts on how the war directly affected the expansion of MicroRNA Therapies. It's important to highlight that geopolitical conflicts can disrupt supply chains, disrupt research collaborations, and undermine investor confidence, thus hindering the development and commercialization of innovative medical innovations like MicroRNA Therapies. However, further in-depth study and industry reports focused on this specific component may be required for exact insights into the war's immediate impact.

 

The key companies profiled in the MicroRNA Therapies Market Report are listed below:

● Thermo Fisher Scientific, Inc. 

● Regulus Therapeutics 

● Horizon Discovery Ltd. 

● QIAGEN 

● GeneCopoeia 

● New England Biolabs 

● Quantabio 

● BioGenex 

● SeqMatic LLC 

● Sistemic Scotland Limited

● Miltenyi Biotec

● OriGene Technologies, Inc.

● miRecule

● Rosetta Genomics

● Merck KGaA

 RNA Sequencing Market - Forecast (2024 - 2030)- RNA Sequencing Market size is estimated to reach $4.9 billion by 2027, growing at a CAGR of 23.4% during the forecast period 2022-2027. RNA Sequencing is a chain approach that utilizes next-generation sequencing (NGS) to disclose the existence and amount of RNA in a biological sample at a given moment, evaluating the continued altering cellular transcriptome.

Next Generation Sequencing Market – Forecast (2024 - 2030)- The global Next Generation Sequencing market is estimated to grow at a CAGR of 17.25% during the forecast period 2019–2025. The market is projected to grow from $4,570Mn in 2018 to $13,714Mn by 2025. Next Generation Sequencing (NGS) is a mixture of techniques used in diagnosing and treating various diseases. Next-generation sequencing (NGS) is emerging as a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors.

RNA Interference Market – Forecast (2024 - 2030)- The RNA Interference Market size is estimated to reach $45.2 billion by 2027. Furthermore, it is poised to grow at a CAGR of 14.7% over the forecast period of 2022-2027. mRNA molecules have been the most utilized biochemical tool that has helped in the regulation of the predominant gene expression.

IndustryARC primarily focuses on Market Research and Consulting Services specific to Cutting Edge Technologies and Newer Application segments of the market. The company’s Custom Research Services are designed to provide insights into the constant flux in the global demand-supply gap of markets.  

IndustryARC’s goal is to provide the right information required by the stakeholder at the right point in time, in a format which assists an intelligent and informed decision-making process.

 

Mr. Venkat Reddy

IndustryARC

Email: [email protected]

USA: (+1) 970-236-3677

Web: https://www.industryarc.com

Follow us on:LinkedIn | Facebook | Twitter